Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC May File Contempt Charges Against Enforma Expert Witness, Lawyers

This article was originally published in The Tan Sheet

Executive Summary

The FTC is considering filing a motion to hold Enforma Natural Products expert witness Harry Preuss, MD, Georgetown University School of Medicine, and outside counsel Edward Glynn and Gary Hailey in contempt of court for violating a May 2000 consent decree

You may also be interested in...



Ad Claims Heightened Media Screening Essential – FTC’s Anthony

FTC efforts to encourage responsible review of advertising claims among media outlets have elicited, at best, a "lukewarm" response, Commissioner Sheila Anthony told the Food & Drug Law Institute annual educational conference April 16

FTC v. Enforma

Commission, Enforma Natural Products jointly ask Los Angeles federal Judge Spencer Letts to appoint UCLA researcher David Heber, MD/PhD, as an expert to evaluate scientific issues involving Enforma's Fat Trapper Plus and Exercise In A Bottle weight-loss products. Parties will submit briefs April 17 on proposed issues to be evaluated by Heber if he receives court approval. FTC alleges Enforma has "blatantly disregarded" a May 2000 order by continuing to make unsubstantiated claims for the products. Heber is director of UCLA's botanical dietary supplements research center...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel